307 related articles for article (PubMed ID: 31578597)
21. Chronic kidney disease: effects on the cardiovascular system.
Schiffrin EL; Lipman ML; Mann JF
Circulation; 2007 Jul; 116(1):85-97. PubMed ID: 17606856
[TBL] [Abstract][Full Text] [Related]
22. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients.
Liabeuf S; Lenglet A; Desjardins L; Neirynck N; Glorieux G; Lemke HD; Vanholder R; Diouf M; Choukroun G; Massy ZA;
Kidney Int; 2012 Dec; 82(12):1297-303. PubMed ID: 22895515
[TBL] [Abstract][Full Text] [Related]
23. Association of Zinc Deficiency with Development of CVD Events in Patients with CKD.
Nakatani S; Mori K; Shoji T; Emoto M
Nutrients; 2021 May; 13(5):. PubMed ID: 34063377
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention.
Ardhanari S; Alpert MA; Aggarwal K
Adv Perit Dial; 2014; 30():40-53. PubMed ID: 25338421
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Uremic Toxicity Induced Inflammatory Response on the Cardiovascular Burden in Chronic Kidney Disease.
Claro LM; Moreno-Amaral AN; Gadotti AC; Dolenga CJ; Nakao LS; Azevedo MLV; de Noronha L; Olandoski M; de Moraes TP; Stinghen AEM; Pécoits-Filho R
Toxins (Basel); 2018 Sep; 10(10):. PubMed ID: 30249039
[TBL] [Abstract][Full Text] [Related]
26. Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome.
Lekawanvijit S
Toxins (Basel); 2018 Sep; 10(9):. PubMed ID: 30200452
[TBL] [Abstract][Full Text] [Related]
27. Risk of stroke in kidney disease.
Ninomiya T
Contrib Nephrol; 2013; 179():58-66. PubMed ID: 23652449
[TBL] [Abstract][Full Text] [Related]
28. Insulin resistance and the metabolic syndrome are associated with arterial stiffness in patients with chronic kidney disease.
Chan DT; Watts GF; Irish AB; Ooi EM; Dogra GK
Am J Hypertens; 2013 Sep; 26(9):1155-61. PubMed ID: 23736110
[TBL] [Abstract][Full Text] [Related]
29. Arterial location-specific calcification at the carotid artery and aortic arch for chronic kidney disease, diabetes mellitus, hypertension, and dyslipidemia.
Yamada S; Oshima M; Watanabe Y; Miyake H
Calcif Tissue Int; 2014 Sep; 95(3):267-74. PubMed ID: 25017195
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment?
Bazyluk A; Malyszko J; Zbroch E
Postgrad Med; 2018 Jun; 130(5):461-469. PubMed ID: 29846140
[TBL] [Abstract][Full Text] [Related]
31. [Erythrocyte abnormalities and their possible role in cardiovascular complications of uremia].
Bonomini M; Arduini A; Sirolli V; Di Pietro N; Pandolfi A
G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177098
[TBL] [Abstract][Full Text] [Related]
32. Chronic kidney disease, diabetes mellitus and cardiovascular disease: risks and commonalities.
Suckling R; Gallagher H
J Ren Care; 2012 Feb; 38 Suppl 1():4-11. PubMed ID: 22348359
[TBL] [Abstract][Full Text] [Related]
33. The MAURO study: baseline characteristics and compliance with guidelines targets.
Leonardis D; Mallamaci F; Enia G; Postorino M; Tripepi G; Zoccali C;
J Nephrol; 2012; 25(6):1081-90. PubMed ID: 23172127
[TBL] [Abstract][Full Text] [Related]
34. Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease.
Ravid JD; Kamel MH; Chitalia VC
Nat Rev Nephrol; 2021 Jun; 17(6):402-416. PubMed ID: 33758363
[TBL] [Abstract][Full Text] [Related]
35. The role of lipids and uremic toxins in cardiovascular disease in CKD.
Massy ZA
Clin Exp Nephrol; 2014 Apr; 18(2):255-6. PubMed ID: 24072415
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular risk factors among patients with chronic kidney disease attending a tertiary hospital in Uganda.
Babua C; Kalyesubula R; Okello E; Kakande B; Sebatta E; Mungoma M; Mondo CK
Cardiovasc J Afr; 2015; 26(4):177-80. PubMed ID: 26407219
[TBL] [Abstract][Full Text] [Related]
37. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia.
Yamada S; Tokumoto M; Tatsumoto N; Taniguchi M; Noguchi H; Nakano T; Masutani K; Ooboshi H; Tsuruya K; Kitazono T
Am J Physiol Renal Physiol; 2014 Jun; 306(12):F1418-28. PubMed ID: 24808541
[TBL] [Abstract][Full Text] [Related]
38. Con: vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease.
Zoccali C; London G
Nephrol Dial Transplant; 2015 Mar; 30(3):352-7. PubMed ID: 25712936
[TBL] [Abstract][Full Text] [Related]
39. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?
Scarpioni R; Ricardi M; Melfa L; Cristinelli L
Cardiovasc Ther; 2010 Dec; 28(6):361-8. PubMed ID: 20553296
[TBL] [Abstract][Full Text] [Related]
40. [Chronic renal disease, inflammation and atherosclerosis: new concepts about an old problem].
Dummer CD; Thomé FS; Veronese FV
Rev Assoc Med Bras (1992); 2007; 53(5):446-50. PubMed ID: 17952355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
